Focused On-demand Library for Exosome complex component RRP40

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NQT5

UPID:

EXOS3_HUMAN

Alternative names:

Exosome component 3; Ribosomal RNA-processing protein 40; p10

Alternative UPACC:

Q9NQT5; A8K0K6; Q5QP85; Q9Y3A8

Background:

Exosome complex component RRP40, also known as Exosome component 3 and Ribosomal RNA-processing protein 40, plays a crucial role in RNA processing and degradation. It is a non-catalytic component of the RNA exosome complex, involved in the maturation of stable RNA species, elimination of RNA processing by-products, and degradation of unstable mRNAs. Its activity is essential in both nuclear and cytoplasmic environments.

Therapeutic significance:

The association of RRP40 with Pontocerebellar hypoplasia 1B, a severe neurologic disorder, underscores its potential as a target for therapeutic intervention. Understanding the role of RRP40 could open doors to potential therapeutic strategies.